MicroPort MedBot (2252.HK): China Healthcare Corporate Day 2026 Takeaways: overseas roll out on track; differentiated strategy supports

Research evidence excerpt

MicroPort MedBot (2252.HK): China Healthcare Corporate Day 2026 Takeaways: overseas roll out on track; differentiated strategy supports

Equity Research

25 June 2026 | 6:28PM HKT

MicroPort MedBot (2252.HK): China Healthcare Corporate Day 2026

Takeaways — overseas roll out on track; differentiated strategy supports

Chris Pan, CFA

+852-2978-7993 | chris.pan@gs.com

Goldman Sachs (Asia) L.L.C.

Ziyi Chen

+852-2978-0526 | ziyi.chen@gs.com

Presenters: Board Secretary

Bottom line: Toumai’s overseas commercialization continued to broaden, with

cumulative commercial orders reaching c.300 globally, including 240+ from overseas.

With 100 systems installed YTD, management reiterated confidence in delivering its

2026 full-year guidance of 200 installations, Rmb1.1bn revenue and full-year

breakeven, supported by continued emerging-market traction, first-mover strategy

in new markets, differentiated remote surgery capability and parent-company

overseas infrastructure.

Key Takeaways

n Overseas roll out broadening; emerging-market traction and Europe

expansion keep FY26 targets on track: Toumai’s global roll out continued to

broaden, with commercial installations now spanning more than 60 countries

and regions. Since the beginning of 2026, Toumai has newly entered over ten

countries or markets, including Saudi Arabia and South Korea, and has obtained

market access in over 40 additional countries. Overseas markets continued to

track well, especially in populous emerging markets across Southeast Asia and

Latin America; for example, India has grown from its first order last year to 30+

cumulative orders currently, while Brazil and Argentina have each reached nearly

20 cumulative orders. In Europe, Toumai has secured orders across Italy, Spain,

Belgium, the UK and France.